More on JAGX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.67 |
|
|||
| Open | $2.67 | ||||
| 52 Wk High | $4.60 | ||||
| 52 Wk Low | $0.81 | ||||
| Day High | $2.67 | ||||
| Day Low | $2.67 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,711 | ||||
- FDA grants Jaguar Health fee waivers for two drugs in fiscal 2027
- Jaguar Health Receives Fee Waivers from FDA
- Form 8-K Jaguar Health, Inc. For: Sep 15
- Form PRE 14A Jaguar Health, Inc. For: Oct 23
- Form 8-K Jaguar Health, Inc. For: Sep 11
- Form 8-K Jaguar Health, Inc. For: Sep 14
- Jaguar Health announces 1-for-15 reverse stock split on Nasdaq
- Jaguar Health, Inc. Announces Reverse Stock Split
- Jaguar Health MVID trial moves to extension phase ahead of 2027 NDA
- All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu
Entities mentioned with JAGX
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Show More...
